Cellular therapy services provided by blood centers and hospitals in the United States, 1999: an analysis from the Nationwide Blood Collection and Utilization Survey.

Abstract

The 2000 Nationwide Blood Collection and Utilization Survey was designed to assess cellular therapy product services in US blood centers and hospitals. Questionnaires were returned by 2,040 institutions. Data were analyzed for 30 quantitative variables related to cellular therapy product activities. 269 institutions, including 231 (12.2%) of the hospitals, 37 (25.9%) of the blood centers, and one cryobank, performed HPC services. Collected PBSC (20,517) and cord blood products (12,628) far exceeded bone marrow (1,572), lymphocytes (578), and cultured cells (344). PBPC collections dropped 36.5 percent since the 1997 survey. Cord blood accounted for 35.4 percent of collections and 39.5 percent of products processed, but only 1.9 percent of infusions. Most cellular therapy services in hospitals and blood centers were HPC-related. The dramatic drop in PBPC collections since 1997 reflects the decline in autologous PBPC transplantation for breast cancer. Cord blood's high collection-to-infusion ratio demonstrates a substantial resource expenditure for banking a product for future clinical needs. Lymphocytes and cultured cell products contributed minimally to activities in this survey, but will likely increase in the future. Data from additional academic and commercial manufacturers of cellular therapy products should be included in future surveys.